Categories: Wire Stories

ReNAgade to Present at the Upcoming 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced that Amit D. Munshi, Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 8:30 a.m. PT in San Francisco, CA.


About ReNAgade Therapeutics

ReNAgade exists to unlock the potential for RNA medicines to treat disease anywhere in the body. We combine our novel RNA delivery platforms with a comprehensive RNA platform allowing for an all-RNA system for coding, editing, and gene insertion to develop new medicines.

To accelerate the future of medicine, we bring together a team with deep RNA and delivery expertise to develop paradigm-shifting RNA medicines.

ReNAgade Therapeutics—RNA Without Limits

For more information about the company, its technologies, and its leadership, visit www.renagadetx.com

Contacts

Investor Relations:

Emily Brabbit, Argot Partners

(212) 600-1902

renagade@argotpartners.com

Media Relations:

Sarah Sutton, Argot Partners

(212) 600-1902

renagade@argotpartners.com

Alex

Recent Posts

Zhengzhou: Interactive Exhibitions on the International Museum Day

ZHENGZHOU, China--(BUSINESS WIRE)--In central China’s Zhengzhou city, visiting museums has become a new trend of…

6 hours ago

Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally

Mollie Pearce, star of the UK reality TV show ‘The Traitors’ who was diagnosed with…

16 hours ago

Quality Building Award 2024 Unveils Finalist List

QBA 2024 Announces 35 Finalists Competing for Hong Kong's Highest Honour in the Building Industry…

2 days ago

UXLINK Tops RootData’s Latest X Hot Items List and DappRadar Social Apps List

SINGAPORE - Media OutReach Newswire - 17 May 2024 - UXLINK, the Web3 social platform…

2 days ago

Australia Construction Industry Report 2024: Growth to Slow to 2% in Real-terms this Year Following 9% Growth in 2023 – Forecasts to 2028 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Australia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to…

2 days ago

Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast

Three-part podcast interview features The mechanism of action of ANKTIVA® activating NK cells, Killer T…

2 days ago